Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Rating) have been given an average rating of “Hold” by the eleven ratings firms that are currently covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $28.25.
Several brokerages have recently issued reports on ARCT. Brookline Capital Management reaffirmed a “buy” rating on shares of Arcturus Therapeutics in a research report on Wednesday, August 10th. Robert W. Baird cut shares of Arcturus Therapeutics from a “neutral” rating to an “underperform” rating and set a $18.00 price objective for the company. in a research report on Thursday, November 10th. StockNews.com raised shares of Arcturus Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday. Barclays raised shares of Arcturus Therapeutics from an “underweight” rating to an “equal weight” rating and boosted their price target for the company from $16.00 to $25.00 in a report on Wednesday, November 2nd. Finally, Cantor Fitzgerald upped their target price on shares of Arcturus Therapeutics from $39.00 to $44.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 2nd.
Institutional Investors Weigh In On Arcturus Therapeutics
A number of institutional investors have recently made changes to their positions in ARCT. Balyasny Asset Management LLC raised its holdings in Arcturus Therapeutics by 3,039.8% during the 3rd quarter. Balyasny Asset Management LLC now owns 339,383 shares of the biotechnology company’s stock valued at $5,030,000 after buying an additional 328,574 shares during the last quarter. BNP Paribas Arbitrage SNC grew its position in shares of Arcturus Therapeutics by 1,096.8% in the 3rd quarter. BNP Paribas Arbitrage SNC now owns 60,353 shares of the biotechnology company’s stock worth $894,000 after buying an additional 55,310 shares during the period. Vanguard Group Inc. grew its position in shares of Arcturus Therapeutics by 12.0% in the 3rd quarter. Vanguard Group Inc. now owns 1,336,818 shares of the biotechnology company’s stock worth $19,812,000 after buying an additional 143,162 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Arcturus Therapeutics by 9.1% in the 3rd quarter. Price T Rowe Associates Inc. MD now owns 18,247 shares of the biotechnology company’s stock worth $271,000 after buying an additional 1,515 shares during the period. Finally, Formidable Asset Management LLC grew its position in Arcturus Therapeutics by 4.7% during the 3rd quarter. Formidable Asset Management LLC now owns 15,650 shares of the biotechnology company’s stock valued at $261,000 after purchasing an additional 700 shares during the last quarter. Hedge funds and other institutional investors own 83.55% of the company’s stock.
Arcturus Therapeutics Price Performance
About Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc, an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU.
- Get a free copy of the StockNews.com research report on Arcturus Therapeutics (ARCT)
- Institutional Support for Analog Devices Remains High
- Is the 60/40 Portfolio Mix Still in Vogue?
- Microsoft Shares: Is it Time to Back Up the Truck?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.